<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318252</url>
  </required_header>
  <id_info>
    <org_study_id>C-10-080</org_study_id>
    <nct_id>NCT01318252</nct_id>
  </id_info>
  <brief_title>AL-54478 Proof of Concept Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of AL-54478 0.005% compared
      with Latanoprost 0.005% and AL-54478 Vehicle in patients with open-angle glaucoma or ocular
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Area Under the Curve (AUC) for IOP Change from Baseline after 14 Days of Once Daily Dosing</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Open-angle Glaucoma (OAG)</condition>
  <condition>Ocular Hypertension (OHT)</condition>
  <arm_group>
    <arm_group_label>AL-54478</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-54478 0.005%, single dose, followed 7 days later with 14 days of once daily dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost 0.005%, single dose, followed 7 days later with 14 days of once daily dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AL-54478 Vehicle, single dose, followed 7 days later with 14 days of once daily dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-54478 0.005%</intervention_name>
    <arm_group_label>AL-54478</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005%</intervention_name>
    <arm_group_label>Latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-54478 Vehicle</intervention_name>
    <description>Inactive ingredients used as a placebo comparator</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with either OAG or OHT.

          -  Patients who are able to comply with the scheduled visits.

          -  Patients who have had a physical exam within 6 months of the Screening Visit.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Females of childbearing potential who meet any 1 of the following conditions: a)
             Currently pregnant; b) Positive urine pregnancy test; c)Intend to become pregnant; d)
             Breast feeding; e) Not using highly effective birth control measures.

          -  Patients with extreme narrow angle with complete or partial closure.

          -  Patients with a cup to disc ratio more than 0.8.

          -  Patients with a severe central visual field loss in either eye.

          -  Patients with chronic or recurrent inflammatory eye disease or acute ocular infection
             or inflammation.

          -  Patients who have had ocular trauma within the past 6 months or have had intraocular
             surgery within the past 6 months or have had ocular laser surgery within the past 3
             months.

          -  Patients with best-correct visual acuity less than 20/80.

          -  Patients who have had ocular infection or inflammation within the past 3 months.

          -  Patients who have clinically relevant progressive retinal disease.

          -  Patients who have severe illness or conditions.

          -  Patients who have hypersensitivity to a prostaglandin analogu.e

          -  Patients who are unable to safely discontinue all IOP-lowering medications during
             washout.

          -  Patients who are currently on therapy with another investigational agent within 30
             days prior to the Screening Visit.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravaughn Williams</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <disposition_first_submitted>July 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 31, 2014</disposition_first_posted>
  <last_update_submitted>July 28, 2014</last_update_submitted>
  <last_update_submitted_qc>July 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elevated IOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

